Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.67 |
| ▸ | NPY1R | P25929 | 10/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.67 |
| ▸ | NPY2R | P49146 | 6/20 | 0.67 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314376 | 0.99 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29574373 | 0.96 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30392718 | 0.94 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3993177 | 0.94 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3303678 | 0.94 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7248017 | 0.94 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30866929 | 0.93 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29969342 | 0.93 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30334190 | 0.93 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30849955 | 0.93 | NPY4R (0.76) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007273-B2 | Prochelators as targeted prodrugs for prostate cancer and methods of making and using same | DUKE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200171160-A1 | PROCHELATORS AS TARGETED PRODRUGS FOR PROSTATE CANCER AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY | 2020-06-04 | — | — | US | disclosed |
| WO-2019010231-A1 | PROCHELATORS AS TARGETED PRODRUGS FOR PROSTATE CANCER AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY (US) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007273-B2 | Prochelators as targeted prodrugs for prostate cancer and methods of making and using same | FOLH1, FAP, BPHL | NPY4R 4078/4885NPY1R 4114/4885NPY5R 4403/4885 |
| US-20200171160-A1 | PROCHELATORS AS TARGETED PRODRUGS FOR PROSTATE CANCER AND METHODS OF MAKING AND USING SAME | FOLH1, FAP, BPHL | NPY4R 4078/4885NPY1R 4114/4885NPY5R 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.